Review of management of type 2 diabetes mellitus

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 6, 1998, Pages 457-465

  Yap, W S ^a   Peterson, Gregory M ^a   Vial, J H ^b   Randall, C T C ^a,c   Greenaway, T M ^c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c ROYAL HOBART HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; AUSTRALIA; BIOCHEMISTRY; BODY MASS; COGNITIVE DEFECT; COMORBIDITY; DIABETES CONTROL; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG USE; FEMALE; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES;

EID: 0032465923     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1998.00185.x     Document Type: Article

References (46)

1. Kowie CC, Eberhardt MS, eds. (1996) Diabetes 1996: Vital statistics. Alexandria, VA: American Diabetes Association.
2. Jarret RJ. (1991) The epidemiology of diabetes mellitus. In: Pickup J, Williams G, eds. Textbook of Diabetes. London: Blackwell, 47.
3. Tan GH, Nelson RL. (1996) Pharmacologic treatment options for non-insulin-dependent diabetes mellitus. Mayo Clinic Proceedings, 71, 763-768.
4. Lefebvre PJ, Scheen AJ. (1992) Management of non-insulin dependent diabetes mellitus. Drugs, 44, 29-37.
5. Gan SC, Barr J, Arieff AI, Pearl RG. (1992) Biguanide associated lactic acidosis. Case report and review of the literature. Archives of Internal Medicine, 152, 2333-2336.
6. Pearlman BL, Fenves AZ, Emmett M. (1996) Metformin-associated lactic acidosis. American Journal of Medicine, 101, 109-110.
7. Jurovich MR, Wooldridge JD, Force RW. (1997) Metformin-associated nonketotic metabolic acidosis. Annuals of Pharmacotherapy, 31, 53-55.
8. Adverse Drug Reactions Advisory Committee Australian Drug Evaluation Committee. (1995) Fatal lactic acidosis with metformin. Australian Adverse Drug Reactions Bulletin, 14(2), 6-7.
9. Goo AKY, Carson DS, Bjelajac A. (1996) Metformin: a new treatment option for non-insulin-dependent diabetes mellitus. Journal of Family Practice, 42, 612-618.
10. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. (1998) Lactic acidosis in patients with diabetes treated with metformin [letter]. New England Journal of Medicine, 338, 265-266.
11. Scheen AJ. (1997) Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs, 54, 355-368.
12. Krentz AJ, Ferner RE, Bailey CJ. (1994) Comparative tolerability profiles of oral antidiabetic agents. Drug Safety, 11, 223-241.
13. Campbell IW. (1985) Metformin and the sulphonylureas: the comparative risk. Hormone and Metabolic Research Supplement 15, 105-111.
14. Sugarman JR. (1991) Hypoglycemia associated hospitalizations in a population with a high prevalence of non-insulin-dependent diabetes mellitus. Diabetes Research and Clinical Practice, 14, 139-148.
15. Asplund K, Wiholm BE, Lithner F. (1983) Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia, 24, 412-417.
16. Meneilly GS, Tessier D. (1995) Diabetes in the elderly. Diabetic Medicine, 12, 949-960.
17. Jonsson A, Rydberg T, Ekberg G, Halengren B, Melander A. (1994) Slow elimination of glyburide in NIDDM subjects. Diabetes Care, 17, 142-145.
18. Rydberg T, Jonsson A, Roder M, Melander A. (1994) Hypoglycemic activity of glyburide (glibenclamide) metabolites in man. Diabetes Care, 17, 1026-1030.
19. Ferner RE, Neil HA. (1988) Sulphonylurea and hypoglycaemia. British Medical Journal, 296, 949.
20. Seltzer HS. (1989) Drug-induced hypoglycemia. A review of 1418 cases. Endocrinology and Metabolism Clinics of North America, 18, 163-183.
21. Jennings AM, Wilson RM, Ward JD. (1989) Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care, 12, 203-208.
22. Gill GV, Huddle KR. (1993) Hypoglycaemic admissions among diabetic patients in Soweto, South Africa. Diabetic Medicine, 10, 181-183.
23. Tessier D, Dawson K, Fetrault JP, Bravo G, Meneilly GS. (1994) Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabetic Medicine, 11, 974-980.
24. Chan TY (1998) Anti-diabetic drugs as a cause of hypoglycaemia among acute medical admissions in Hong Kong and Singapore - relationship to the prescribing patterns in diabetic patients. Singapore Medical Journal, 39, 186-188.
25. Melander A. (1990) Treatment with oral antidiabetic agents. In: Strandberg K, Beermann B, Lonnerholm G, eds. Treatment of Non-Insulin-Dependent Diabetes Mellitus. Uppsala, Sweden: Swedish Medical Products Agency, 87-114.
26. Brodows RG. (1992) Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care, 15, 75-80.
27. Harrower ADB. (1991) Efficacy of gliclazide in comparison with other sulfonylureas in the treatment of NIDDM. Diabetes Research and Clinical Practice, 14(Suppl. 2), S65-S67.
28. Palmer KJ, Brogden RN. (1993) Gliclazide: an update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs, 46, 92-125.
29. Harrower ADB. (1994) Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. Journal of Diabetes and its Complications, 8, 201-203.
30. Cockroft DW, Gault MH. (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41.
31. Thomas, J, ed. (1996) Australian Prescription Products Guide 1996, 25th edn. Melbourne, Victoria: Australian Pharmaceutical Publishing Company Ltd.
32. Bailey CJ, Turner RC. (1996) Metformin. New England Journal of Medicine, 334, 574-579.
33. Therapeutic Guidelines Endocrinology Writing Group. (1997) Therapeutic Guidelines: Endocrinology. Melbourne: Therapeutic Guidelines Limited.
34. United Kingdom Prospective Diabetes Study Group. (1998) UK prospective diabetes study 33: intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 352, 837-853.
35. United Kingdom Prospective Diabetes Study Group. (1998) UK prospective diabetes study 34: effect of intensive blood glucose control policy with metformin on complications in type 2 diabetes patients. Lancet, 352, 854-865.
36. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S. (1995) Intensive insulin therapy prevents the progression of microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomised prospective 6-year study. Diabetes Research and Clinical Practice, 28, 103-117.
37. Wandell PE, Brorsson B, Aberg H. (1997) Drug prescription in diabetic patients in Stockholm in 1992 and 1995 - change over time. European Journal of Clinical Pharmacology, 52, 249-254.
38. Kennedy DL, Piper JM, Baum C. (1988) Trends in use of oral hypoglycemic agents 1964-86. Diabetes Care, 11, 558-562.
39. Paterson JR, Orrell JM, Neithercut WD, et al. (1989) Drug therapy in patients with diabetes mellitus: an audit. Diabetes Research, 12, 169-171.
40. Aguilar C, Reza A, Garcia JE, Rull JA. (1992) Biguanide-related lactic acidosis: incidence and risk factors. Archives of Medical Research, 23, 19-24.
41. Sulkin TV, Bosman D, Krentz AJ. (1997) Contraindications to metformin therapy in patients with NIDDM. Diabetes Care, 20, 925-928.
42. Dunn CJ, Peters DH. (1995) Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs, 49, 721-749.
43. Scheen AJ, Lefebvre PJ. (1993) Pharmacological treatment of the obese diabetic patient. Diabetes and Metabolism, 19, 547-559.
44. Stenman S, Melander A, Groop PH, Groop LC. (1993) What is the benefit of increasing the sulfonylurea dose? Annals of Internal Medicine, 118, 169-172.
45. Holman RR, Turner RC. (1995) Insulin therapy in type II diabetes. Diabetes Research and Clinical Practice, 28(Supplement), S179-S184.
46. Anon. (1998). New oral antihyperglycaemic agents expand armamentarium in the battle against type 2 diabetes mellitus. Drugs and Therapy Perspectives, 12(7), 6-10.